Roche reported that its investigational antisense therapy sefaxersen met phase 3 endpoints in IgA nephropathy, renewing momentum in a kidney market that has expanded rapidly since the first approvals in the condition. The company positioned the results as setting up discussions with regulators and possible accelerated review pathways. Sefaxersen is described as a once-monthly injection and is designed to target RNA relevant to the disease biology. If approved, Roche would be entering an increasingly competitive IgAN landscape where multiple other mechanisms are already on the market. Analysts and clinicians will likely focus on the durability of proteinuria reductions and the robustness of clinical outcomes across patient subgroups as Roche weighs next steps.